-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Hypopharyngeal Cancer Drug Details: XB-002 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APBR-3 in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APBR-3 in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APBR-3 in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)...
-
Company Insights
Innovation and Patenting activity of NGM Biopharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NGM Biopharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lysergic Acid Diethylamide in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lysergic Acid Diethylamide in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lysergic Acid Diethylamide in Cluster Headache...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Osemitamab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Gastric Cancer Drug Details: Osemitamab (TST-001) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-438 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-438 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NGM-438 in Melanoma Drug Details:NGM-438 is under development for the treatment of advanced solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-280 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-280 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darolutamide in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darolutamide in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darolutamide in Metastatic Prostate Cancer Drug Details: Darolutamide (Nubeqa) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SB-11285 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SB-11285 in Triple-Negative Breast Cancer (TNBC) Drug Details: SB-11285 is...